DHEA Supplementation Guidelines
Primary Adrenal Insufficiency
For women with primary adrenal insufficiency experiencing persistent low libido and/or low energy despite optimized glucocorticoid and mineralocorticoid replacement, offer a 6-month trial of DHEA 25 mg once daily in the morning. 1, 2
Pre-Treatment Requirements
Before initiating DHEA, ensure adequate baseline hormone replacement:
Glucocorticoid optimization: Verify hydrocortisone dosing at 15-25 mg daily (typically divided as 10 mg at 07:00,5 mg at 12:00, and 2.5 mg at 16:00) and assess for under-replacement signs including morning fatigue, salt cravings, and lightheadedness. 2
Mineralocorticoid adequacy: Confirm fludrocortisone dosing at 50-200 µg daily (up to 500 µg in younger adults) and evaluate for salt cravings, orthostatic hypotension, and peripheral edema. 2
Baseline laboratory testing: Measure morning serum DHEA sulfate, androstenedione, and testosterone levels before starting therapy. 1, 2
Monitoring Strategy
At 3 months: Recheck DHEA sulfate, androstenedione, and testosterone levels; adjust dose to maintain levels in the normal range for premenopausal women. 1, 2
At 6 months: Assess clinical efficacy for libido, energy, mood, and overall quality of life; continue DHEA only if clinically effective. 1, 2
Long-term: Use with caution as long-term effects are not fully established. 1
Evidence Quality
The recommendation is based on limited objective evidence from large studies, with data supporting small benefits in quality of life and mood but inconsistent effects on sexual function. 1, 3 Studies demonstrate DHEA restores androgen levels, improves well-being and sexual satisfaction in adrenal insufficiency, though results vary across trials. 4, 5
Postmenopausal Vaginal Symptoms
For postmenopausal women with vaginal dryness or dyspareunia, vaginal DHEA (prasterone) can be considered as an alternative to vaginal estrogen, particularly in those without estrogen-dependent cancers. 6
Application in Cancer Survivors
Effectiveness: A randomized controlled trial of 464 breast or gynecologic cancer survivors showed vaginal DHEA significantly improved sexual desire, arousal, pain, and overall sexual function, though plain moisturizer also provided benefit. 6
Critical caution: Use DHEA with extreme caution in patients receiving aromatase inhibitor (AI) therapy, as vaginal DHEA increases circulating androgens that may interfere with AI activity. 6
Safety limitations: Long-term safety data for androgen-based therapy in hormonally mediated cancers remain limited, and the safety of vaginal hormones has not been firmly established in estrogen-dependent cancers. 6
Evidence Nuances
While several studies demonstrate DHEA effectiveness for reducing dyspareunia in postmenopausal individuals, a 2015 systematic review and meta-analysis concluded uncertainty remains regarding whether vaginal DHEA improves vaginal dryness specifically. 6 The evidence suggests DHEA works but may not outperform simpler interventions like moisturizers for all symptoms.
Populations Where DHEA Is NOT Routinely Recommended
Do not routinely prescribe DHEA for anti-aging, menopausal symptoms, sexual function in normal women, or cognitive enhancement, as no consistent beneficial effects have been demonstrated. 3
Specific Contexts
Normal postmenopausal women: No consistent benefits observed for menopausal symptoms, sexual function, cognition, or overall wellbeing. 3
Infertility/diminished ovarian reserve: DHEA use to improve ovulation induction response is not recommended. 3
Male patients with adrenal insufficiency: Effectiveness is unknown as studies focused on female patients. 5
Common Pitfalls to Avoid
Premature DHEA initiation: Do not start DHEA before optimizing glucocorticoid and mineralocorticoid replacement, as symptoms may resolve with proper baseline therapy alone. 1, 2
Inadequate monitoring: Failure to check androgen levels at 3 months risks over-replacement with androgenic side effects (acne, hirsutism, voice changes). 1, 2
Continuing ineffective therapy: Discontinue DHEA at 6 months if no clinical benefit is evident; do not continue indefinitely without documented improvement. 1, 2
Drug interactions: Avoid NSAIDs in patients on fludrocortisone, as they interact and may worsen symptoms. 2